NewLink Genetics Corp (NLNK) Given Average Rating of “Hold” by Analysts
Shares of NewLink Genetics Corp (NASDAQ:NLNK) have been given an average rating of “Hold” by the nine ratings firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $4.75.
Several equities research analysts have recently commented on NLNK shares. Zacks Investment Research raised NewLink Genetics from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a research note on Saturday, August 4th. Bank of America cut their price objective on NewLink Genetics from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Friday, November 2nd. Finally, Stifel Nicolaus downgraded NewLink Genetics from a “buy” rating to a “hold” rating and cut their price objective for the stock from $8.00 to $4.00 in a research report on Wednesday, August 1st.
Institutional investors have recently modified their holdings of the stock. Quantitative Systematic Strategies LLC acquired a new position in shares of NewLink Genetics during the 2nd quarter worth approximately $133,000. Pennsylvania Trust Co acquired a new position in shares of NewLink Genetics during the 2nd quarter worth approximately $395,000. Russell Investments Group Ltd. acquired a new position in shares of NewLink Genetics during the 3rd quarter worth approximately $219,000. Acadian Asset Management LLC acquired a new position in shares of NewLink Genetics during the 2nd quarter worth approximately $1,231,000. Finally, Dimensional Fund Advisors LP raised its position in shares of NewLink Genetics by 432.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 286,338 shares of the biotechnology company’s stock worth $684,000 after purchasing an additional 232,530 shares during the last quarter. Hedge funds and other institutional investors own 44.87% of the company’s stock.
NewLink Genetics (NASDAQ:NLNK) last announced its quarterly earnings results on Thursday, November 1st. The biotechnology company reported ($0.20) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.22. The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $2.10 million. NewLink Genetics had a negative return on equity of 42.27% and a negative net margin of 253.52%. As a group, equities research analysts anticipate that NewLink Genetics will post -1.48 earnings per share for the current fiscal year.
NewLink Genetics Company Profile
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia.
Further Reading: How does inflation affect different investments?
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.